J Infect Public Health . Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections

[tetano]

J Infect Public Health


. 2021 Feb 20;14(5):655-660.
doi: 10.1016/j.jiph.2021.02.006. Online ahead of print.
Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections


S Saqrane ¹ , M A El Mhammedi ² , S Lahrich ¹ , F Laghrib ¹ , Y El Bouabi ¹ , A Farahi ¹ , M Bakasse ¹



Affiliations

• PMID: 33857725
• DOI: 10.1016/j.jiph.2021.02.006

Abstract

The management of SARS-CoV-2 has not yet been clearly determined and is based on potential therapies evaluated during the SARS-CoV and MERS-CoV outbreaks. An emerging potential therapeutic approach currently being evaluated in numerous clinical trials is the remdesivir agent, which acts on COVID-19 by interfering with key steps in the virus replication cycle. It is considered a therapeutic option to be evaluated against COVID-19, based on data on its in vitro and in vivo activity against MERS-CoV and SARS-CoV coronaviruses. In this work, we provide an overview of remdesivir's discovery, mechanism of action, and the current studies exploring its clinical effectiveness. Recommendations for its use against COVID-19 infection are also summarized.

Keywords: COVID-19; Clinical tests; Remdesivir.